data_1j5d_residue save_MolProbity _Software.Sf_category software _Software.Sf_framecode MolProbity _Software.Entry_ID ? _Software.ID 1 _Software.Name MolProbity _Software.Version 4.0 _Software.Details . save_ save_CYRANGE _Software.Sf_category software _Software.Sf_framecode CYRANGE _Software.Entry_ID ? _Software.ID 2 _Software.Name CYRANGE _Software.Version 2.0 _Software.Details . save_ save_Structure_validation_residue _Structure_validation_residue.Sf_category structure_validation _Structure_validation_residue.Sf_framecode Structure_validation_residue _Structure_validation_residue.Entry_ID ? _Structure_validation_residue.List_ID 1 _Structure_validation_residue.PDB_accession_code 1j5d _Structure_validation_residue.Date_analyzed 2016-10-06 loop_ _Residue_analysis_software.Software_ID _Residue_analysis_software.Software_label _Residue_analysis_software.Method_ID _Residue_analysis_software.Method_label _Residue_analysis_software.Entry_ID _Residue_analysis_software.Structure_validation_oneline_list_ID 1 MolProbity . . ? 1 2 CYRANGE . . ? 1 stop_ loop_ _Residue_analysis.ID _Residue_analysis.PDB_model_num _Residue_analysis.Hydrogen_positions _Residue_analysis.MolProbity_flips _Residue_analysis.Cyrange_core_flag _Residue_analysis.Two_letter_chain_ID _Residue_analysis.PDB_strand_ID _Residue_analysis.PDB_residue_no _Residue_analysis.PDB_ins_code _Residue_analysis.PDB_residue_name _Residue_analysis.Assembly_ID _Residue_analysis.Entity_assembly_ID _Residue_analysis.Entity_ID _Residue_analysis.Comp_ID _Residue_analysis.Comp_index_ID _Residue_analysis.Clash_value _Residue_analysis.Clash_source_PDB_atom_name _Residue_analysis.Clash_destination_PDB_atom_name _Residue_analysis.Clash_destination_PDB_strand_ID _Residue_analysis.Clash_destination_PDB_residue_no _Residue_analysis.Clash_destination_PDB_ins_code _Residue_analysis.Clash_destination_PDB_residue_name _Residue_analysis.Cbeta_deviation_value _Residue_analysis.Rotamer_score _Residue_analysis.Rotamer_name _Residue_analysis.Ramachandran_phi _Residue_analysis.Ramachandran_psi _Residue_analysis.Ramachandran_score _Residue_analysis.Ramachandran_evaluation _Residue_analysis.Ramachandran_type _Residue_analysis.Bond_outlier_count _Residue_analysis.Worst_bond _Residue_analysis.Worst_bond_value _Residue_analysis.Worst_bond_sigma _Residue_analysis.Angle_outlier_count _Residue_analysis.Worst_angle _Residue_analysis.Worst_angle_value _Residue_analysis.Worst_angle_sigma _Residue_analysis.RNA_phosphate_perpendicular_outlier _Residue_analysis.RNA_suitness_score _Residue_analysis.RNA_suite_conformer _Residue_analysis.RNA_suite_triage _Residue_analysis.Max_b_factor _Residue_analysis.Tau_angle _Residue_analysis.Omega_dihedral _Residue_analysis.Disulfide_chi1 _Residue_analysis.Disulfide_chi2 _Residue_analysis.Disulfide_chi3 _Residue_analysis.Disulfide_ss_angle _Residue_analysis.Disulfide_ss _Residue_analysis.Disulfide_ss_angle_prime _Residue_analysis.Disulfide_chi2prime _Residue_analysis.Disulfide_chi1prime _Residue_analysis.Outlier_count_separate_geometry _Residue_analysis.Outlier_count _Residue_analysis.Entry_ID _Residue_analysis.Structure_validation_residue_list_ID . 001 nuclear orig full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.468 0.435 0 N-CA-C 107.491 -1.3 . . . . 10.0 107.491 . . . . . . . . . 0 0 . 1 . 001 nuclear orig full ' A' A ' 2' ' ' ASN . . . . . . . . . . . . . 10.1 p30 -73.74 162.71 28.86 Favored 'General case' 0 C--O 1.232 0.17 0 N-CA-C 108.266 -1.013 . . . . 10.0 108.266 173.994 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -107.57 167.12 10.17 Favored 'General case' 0 C--O 1.231 0.103 0 N-CA-C 109.157 -0.682 . . . . 10.0 109.157 169.152 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 4' ' ' THR . . . . . . . . . . . . . 15.1 t -148.74 153.76 38.65 Favored 'General case' 0 N--CA 1.444 -0.77 0 O-C-N 121.149 -0.969 . . . . 10.0 110.684 175.776 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 5' ' ' VAL . . . . . . . . . . . . . 90.5 t -136.44 151.86 28.85 Favored 'Isoleucine or valine' 0 C--O 1.235 0.316 0 N-CA-C 106.387 -1.708 . . . . 10.0 106.387 178.233 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 6' ' ' LYS . . . . . . . . . . . . . 55.6 pttt -110.55 131.91 54.65 Favored 'General case' 0 C--O 1.233 0.218 0 N-CA-C 109.376 -0.602 . . . . 10.0 109.376 177.095 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 7' ' ' MET . . . . . . . . . . . . . 19.4 mtt -73.07 84.77 1.3 Allowed 'General case' 0 N--CA 1.451 -0.389 0 N-CA-C 109.112 -0.699 . . . . 10.0 109.112 -173.864 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 101.81 148.67 21.54 Favored Glycine 0 CA--C 1.525 0.704 0 C-N-CA 124.675 1.131 . . . . 10.0 111.048 179.089 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 9' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -73.89 146.14 44.27 Favored 'General case' 0 CA--C 1.533 0.308 0 C-N-CA 123.977 0.911 . . . . 10.0 109.99 -173.947 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 10' ' ' ASP . . . . . . . . . . . . . 0.1 OUTLIER -39.18 -54.25 1.79 Allowed 'General case' 0 N--CA 1.467 0.424 0 C-N-CA 126.081 1.752 . . . . 10.0 112.41 -179.305 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 14.3 t -54.47 -26.65 32.48 Favored 'General case' 0 CA--C 1.537 0.47 0 C-N-CA 124.632 1.173 . . . . 10.0 112.467 -176.87 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 104.47 62.27 0.66 Allowed Glycine 0 C--N 1.336 0.535 0 N-CA-C 108.847 -1.701 . . . . 10.0 108.847 -175.774 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 13' ' ' ALA . . . . . . . . . . . . . . . -132.18 154.11 49.88 Favored 'General case' 0 N--CA 1.456 -0.128 0 N-CA-C 108.283 -1.006 . . . . 10.0 108.283 174.061 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 14' ' ' LEU . . . . . . . . . . . . . 8.3 mp -66.57 -49.86 65.0 Favored 'General case' 0 N--CA 1.453 -0.32 0 C-N-CA 122.303 0.241 . . . . 10.0 110.777 -172.109 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 34.3 m -46.01 130.72 2.69 Favored 'Isoleucine or valine' 0 CA--C 1.539 0.528 0 C-N-CA 122.889 0.476 . . . . 10.0 112.258 -168.433 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 16' ' ' PHE . . . . . . . . . . . . . 5.5 m-85 -71.39 145.9 49.08 Favored 'General case' 0 N--CA 1.453 -0.288 0 N-CA-C 107.844 -1.169 . . . . 10.0 107.844 178.685 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 24.4 mt-10 -134.85 138.06 28.76 Favored Pre-proline 0 C--O 1.235 0.326 0 O-C-N 123.5 0.5 . . . . 10.0 109.742 167.779 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 18' ' ' PRO . . . . . . . . . . . . . 22.6 Cg_exo -64.91 141.98 49.55 Favored 'Cis proline' 0 CA--C 1.539 0.74 0 N-CA-C 109.349 -1.058 . . . . 10.0 109.349 -15.842 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 19' ' ' SER . . . . . . . . . . . . . 5.5 p -69.94 -33.52 72.23 Favored 'General case' 0 CA--C 1.533 0.309 0 C-N-CA 123.578 0.751 . . . . 10.0 111.744 -174.259 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 2.1 m -125.59 145.17 50.25 Favored 'General case' 0 N--CA 1.451 -0.421 0 N-CA-C 107.86 -1.163 . . . . 10.0 107.86 166.771 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 30.2 m -137.3 160.76 35.38 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.46 0 N-CA-C 105.931 -1.877 . . . . 10.0 105.931 172.751 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 22' ' ' THR . . . . . . . . . . . . . 1.3 p -111.68 153.43 26.43 Favored 'General case' 0 CA--C 1.517 -0.294 0 N-CA-C 109.264 -0.643 . . . . 10.0 109.264 172.506 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 23' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -154.18 157.24 4.56 Favored 'Isoleucine or valine' 0 N--CA 1.446 -0.653 0 N-CA-C 105.913 -1.884 . . . . 10.0 105.913 -162.825 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 24' ' ' LYS . . . . . . . . . . . . . 14.0 mttt -97.08 159.77 14.72 Favored 'General case' 0 CA--C 1.535 0.403 0 CA-C-N 120.618 1.554 . . . . 10.0 113.45 177.864 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 25' ' ' ALA . . . . . . . . . . . . . . . -56.57 102.41 0.08 Allowed 'General case' 0 CA--C 1.542 0.673 0 C-N-CA 124.854 1.262 . . . . 10.0 110.563 172.19 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 98.22 -4.7 60.64 Favored Glycine 0 CA--C 1.525 0.714 0 C-N-CA 125.958 1.742 . . . . 10.0 112.772 -179.851 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 27' ' ' GLU . . . . . . . . . . . . . 3.9 mm-40 -73.61 172.06 12.08 Favored 'General case' 0 C--O 1.239 0.534 0 CA-C-N 117.992 0.896 . . . . 10.0 109.196 168.136 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 28' ' ' GLU . . . . . . . . . . . . . 52.6 mt-10 -101.77 161.66 13.49 Favored 'General case' 0 C--O 1.234 0.279 0 CA-C-N 115.215 -0.902 . . . . 10.0 113.178 177.923 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 93.4 t -117.44 142.9 29.48 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.392 0 N-CA-C 107.444 -1.317 . . . . 10.0 107.444 152.911 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 28.0 ttmt -111.26 134.51 52.8 Favored 'General case' 0 CA--C 1.534 0.36 0 CA-C-O 118.683 -0.675 . . . . 10.0 109.404 167.753 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 31' ' ' TRP . . . . . . . . . . . . . 29.4 m-90 -105.77 129.2 54.01 Favored 'General case' 0 CA--C 1.531 0.239 0 CA-C-N 119.585 1.084 . . . . 10.0 108.552 167.868 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 53.5 t -106.93 126.87 62.9 Favored 'Isoleucine or valine' 0 C--N 1.343 0.295 0 C-N-CA 124.526 1.13 . . . . 10.0 108.91 179.946 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 33' ' ' ASN . . . . . . . . . . . . . 34.7 t30 -73.94 102.51 4.14 Favored 'General case' 0 CA--C 1.532 0.258 0 CA-C-O 118.902 -0.571 . . . . 10.0 109.858 -178.443 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 34' ' ' ASN . . . . . . . . . . . . . 17.8 t30 -79.5 -74.16 0.31 Allowed 'General case' 0 CA--C 1.532 0.277 0 CA-C-N 118.683 0.674 . . . . 10.0 110.303 176.68 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 35' ' ' LYS . . . . . . . . . . . . . 3.7 mmtt -166.17 173.98 9.7 Favored 'General case' 0 C--O 1.226 -0.177 0 N-CA-C 108.261 -1.014 . . . . 10.0 108.261 -169.915 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 36' ' ' LEU . . . . . . . . . . . . . 1.7 mm? 68.37 57.63 0.45 Allowed 'General case' 0 N--CA 1.469 0.477 0 C-N-CA 125.331 1.452 . . . . 10.0 108.184 -168.563 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 37' ' ' SER . . . . . . . . . . . . . 1.7 p -77.06 158.01 80.55 Favored Pre-proline 0 N--CA 1.447 -0.577 0 C-N-CA 124.027 0.931 . . . . 10.0 109.744 173.531 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 38' ' ' PRO . . . . . . . . . . . . . 85.6 Cg_endo -76.39 146.28 84.24 Favored 'Cis proline' 0 N--CA 1.456 -0.677 0 N-CA-C 110.02 -0.8 . . . . 10.0 110.02 -8.944 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 39' ' ' HIS . . . . . . . . . . . . . 84.6 m-70 -109.69 146.42 34.9 Favored 'General case' 0 N--CA 1.457 -0.084 0 N-CA-C 109.447 -0.575 . . . . 10.0 109.447 166.03 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 40' ' ' ASN . . . . . . . . . . . . . 3.1 m-20 -116.63 171.47 7.85 Favored 'General case' 0 N--CA 1.452 -0.343 0 N-CA-C 104.343 -2.466 . . . . 10.0 104.343 156.66 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 41' ' ' ILE . . . . . . . . . . . . . 2.8 mt -139.95 88.12 0.51 Allowed 'Isoleucine or valine' 0 C--O 1.225 -0.191 0 N-CA-C 104.41 -2.441 . . . . 10.0 104.41 171.387 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 42' ' ' VAL . . . . . . . . . . . . . 29.3 t -95.36 132.02 40.56 Favored 'Isoleucine or valine' 0 CA--C 1.53 0.187 0 N-CA-C 108.384 -0.969 . . . . 10.0 108.384 -172.452 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 43' ' ' PHE . . . . . . . . . . . . . 4.5 m-85 -107.48 133.1 52.47 Favored 'General case' 0 C--N 1.343 0.284 0 C-N-CA 124.191 0.996 . . . . 10.0 108.932 -170.525 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 44' ' ' ALA . . . . . . . . . . . . . . . -88.68 133.13 34.3 Favored 'General case' 0 CA--C 1.537 0.446 0 CA-C-N 118.555 0.616 . . . . 10.0 109.853 -177.346 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 45' ' ' ALA . . . . . . . . . . . . . . . -76.93 61.63 1.98 Allowed 'General case' 0 C--N 1.341 0.234 0 C-N-CA 123.58 0.752 . . . . 10.0 109.286 174.672 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 46' ' ' ASP . . . . . . . . . . . . . 13.2 t70 -83.72 -57.97 3.0 Favored 'General case' 0 N--CA 1.458 -0.072 0 CA-C-O 120.966 0.412 . . . . 10.0 111.149 -158.876 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . -121.83 32.61 4.55 Favored Glycine 0 CA--C 1.523 0.557 0 N-CA-C 109.1 -1.6 . . . . 10.0 109.1 168.697 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 48' ' ' VAL . . . . . . . . . . . . . 1.7 t -145.94 153.02 13.62 Favored 'Isoleucine or valine' 0 CA--C 1.532 0.287 0 N-CA-C 108.754 -0.832 . . . . 10.0 108.754 -178.318 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 49' ' ' ASP . . . . . . . . . . . . . 0.9 OUTLIER -61.29 155.0 22.23 Favored 'General case' 0 C--O 1.234 0.247 0 C-N-CA 124.87 1.268 . . . . 10.0 112.893 -173.114 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -60.62 -57.77 11.29 Favored 'General case' 0 N--CA 1.451 -0.385 0 C-N-CA 123.873 0.869 . . . . 10.0 110.946 -177.969 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 51' ' ' ASP . . . . . . . . . . . . . 0.9 OUTLIER -52.21 -55.64 19.79 Favored 'General case' 0 CA--C 1.527 0.079 0 CA-C-N 118.9 0.773 . . . . 10.0 111.445 -178.374 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 52' ' ' THR . . . . . . . . . . . . . 0.3 OUTLIER -51.88 -57.25 9.92 Favored 'General case' 0 N--CA 1.465 0.32 0 N-CA-C 109.757 -0.46 . . . . 10.0 109.757 177.409 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 53' ' ' ALA . . . . . . . . . . . . . . . -57.56 -34.75 69.52 Favored 'General case' 0 N--CA 1.448 -0.574 0 N-CA-C 109.841 -0.429 . . . . 10.0 109.841 -178.271 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 54' ' ' ALA . . . . . . . . . . . . . . . -69.06 -46.97 66.5 Favored 'General case' 0 C--N 1.332 -0.171 0 N-CA-C 109.608 -0.516 . . . . 10.0 109.608 -177.443 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 55' ' ' LYS . . . . . . . . . . . . . 66.4 tttt -61.69 -41.92 98.23 Favored 'General case' 0 CA--C 1.536 0.436 0 C-N-CA 123.793 0.837 . . . . 10.0 109.924 178.847 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 56' ' ' LEU . . . . . . . . . . . . . 0.6 OUTLIER -71.14 -26.53 63.04 Favored 'General case' 0 CA--C 1.539 0.554 0 C-N-CA 124.473 1.109 . . . . 10.0 112.505 173.829 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 57' ' ' SER . . . . . . . . . . . . . 14.4 t -73.73 103.78 4.41 Favored 'General case' 0 C--O 1.233 0.201 0 CA-C-N 119.272 0.942 . . . . 10.0 110.666 -178.054 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 58' ' ' HIS . . . . . . . . . . . . . 81.9 m-70 -72.23 92.59 1.39 Allowed 'General case' 0 N--CA 1.45 -0.474 0 O-C-N 121.236 -0.915 . . . . 10.0 108.862 174.517 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 59' ' ' LYS . . . . . . . . . . . . . 82.3 mttt -68.24 -6.82 25.74 Favored 'General case' 0 CA--C 1.54 0.58 0 CA-C-N 115.184 -0.916 . . . . 10.0 111.206 157.175 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . -56.23 156.22 11.82 Favored Glycine 0 CA--C 1.533 1.166 0 N-CA-C 111.08 -0.808 . . . . 10.0 111.08 168.988 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 61' ' ' LEU . . . . . . . . . . . . . 0.3 OUTLIER -132.23 90.34 2.79 Favored 'General case' 0 CA--C 1.531 0.239 0 N-CA-C 107.394 -1.336 . . . . 10.0 107.394 -162.143 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 62' ' ' ALA . . . . . . . . . . . . . . . -90.55 112.59 24.33 Favored 'General case' 0 CA--C 1.531 0.239 0 C-N-CA 123.365 0.666 . . . . 10.0 110.06 -170.247 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 63' ' ' PHE . . . . . . . . . . . . . 0.1 OUTLIER -111.8 -47.88 3.11 Favored 'General case' 0 C--N 1.341 0.205 0 CA-C-N 118.611 0.642 . . . . 10.0 111.375 168.213 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . -71.43 126.82 30.66 Favored 'General case' 0 CA--C 1.539 0.546 0 CA-C-N 118.511 0.596 . . . . 10.0 110.48 -176.166 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 65' ' ' ALA . . . . . . . . . . . . . . . -70.82 91.01 0.82 Allowed 'General case' 0 CA--C 1.532 0.273 0 O-C-N 121.664 -0.648 . . . . 10.0 109.393 -178.766 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . 169.07 -50.8 0.22 Allowed Glycine 0 CA--C 1.523 0.537 0 N-CA-C 110.204 -1.158 . . . . 10.0 110.204 -172.135 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 67' ' ' GLU . . . . . . . . . . . . . 51.7 mt-10 -71.32 96.16 1.4 Allowed 'General case' 0 N--CA 1.449 -0.481 0 N-CA-C 108.047 -1.094 . . . . 10.0 108.047 -177.363 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -78.67 167.22 21.55 Favored 'General case' 0 N--CA 1.446 -0.655 0 N-CA-C 108.404 -0.962 . . . . 10.0 108.404 170.792 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 69' ' ' PHE . . . . . . . . . . . . . 17.8 m-85 -130.28 162.59 28.65 Favored 'General case' 0 C--O 1.231 0.124 0 N-CA-C 108.976 -0.75 . . . . 10.0 108.976 166.934 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 70' ' ' THR . . . . . . . . . . . . . 1.4 m -131.53 152.19 50.95 Favored 'General case' 0 N--CA 1.463 0.203 0 C-N-CA 125.756 1.622 . . . . 10.0 109.945 178.917 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 71' ' ' SER . . . . . . . . . . . . . 14.5 p -145.53 144.99 30.86 Favored 'General case' 0 CA--C 1.543 0.674 0 C-N-CA 125.467 1.507 . . . . 10.0 107.032 176.378 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 72' ' ' THR . . . . . . . . . . . . . 4.3 m -103.05 134.23 46.83 Favored 'General case' 0 N--CA 1.467 0.413 0 C-N-CA 124.613 1.165 . . . . 10.0 108.481 175.48 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 73' ' ' PHE . . . . . 0.489 ' CE2' ' CD1' ' A' ' 79' ' ' TYR . 4.4 m-85 -102.07 91.93 4.55 Favored 'General case' 0 CA--C 1.519 -0.248 0 N-CA-C 107.455 -1.313 . . . . 10.0 107.455 175.17 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 74' ' ' THR . . . . . . . . . . . . . 3.1 m -68.17 -45.71 72.72 Favored 'General case' 0 CA--C 1.532 0.253 0 CA-C-N 118.537 0.608 . . . . 10.0 110.535 -178.149 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 75' ' ' GLU . . . . . . . . . . . . . 35.6 tt0 -90.47 135.07 29.87 Favored Pre-proline 0 CA--C 1.538 0.483 0 C-N-CA 123.355 0.662 . . . . 10.0 110.716 -171.679 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 76' ' ' PRO . . . . . . . . . . . . . 96.2 Cg_endo -75.49 84.86 1.66 Allowed 'Trans proline' 0 N--CA 1.453 -0.883 0 C-N-CA 122.93 2.42 . . . . 10.0 111.093 -178.652 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 77' ' ' GLY . . . . . . . . . . . . . . . -128.92 -159.61 10.0 Favored Glycine 0 CA--C 1.529 0.964 0 C-N-CA 123.75 0.69 . . . . 10.0 111.611 179.318 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 78' ' ' THR . . . . . . . . . . . . . 22.3 m -122.95 135.52 54.52 Favored 'General case' 0 N--CA 1.453 -0.29 0 N-CA-C 105.416 -2.068 . . . . 10.0 105.416 164.738 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 79' ' ' TYR . . . . . 0.489 ' CD1' ' CE2' ' A' ' 73' ' ' PHE . 44.4 m-85 -116.27 142.36 46.94 Favored 'General case' 0 CA--C 1.521 -0.153 0 N-CA-C 106.38 -1.711 . . . . 10.0 106.38 179.153 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 80' ' ' THR . . . . . . . . . . . . . 98.0 m -123.43 142.0 51.43 Favored 'General case' 0 C--O 1.237 0.408 0 N-CA-C 106.79 -1.559 . . . . 10.0 106.79 -178.735 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 81' ' ' TYR . . . . . . . . . . . . . 53.0 p90 -147.03 158.81 44.04 Favored 'General case' 0 N--CA 1.445 -0.692 0 O-C-N 123.776 0.672 . . . . 10.0 111.053 -173.344 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 82' ' ' TYR . . . . . . . . . . . . . 1.3 p90 -158.68 172.78 17.64 Favored 'General case' 0 N--CA 1.449 -0.482 0 C-N-CA 124.094 0.958 . . . . 10.0 109.391 -168.819 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 83' ' ' CYS . . . . . . . . . . . . . 10.4 t -132.09 63.81 1.61 Allowed 'General case' 0 CA--C 1.532 0.263 0 C-N-CA 123.81 0.844 . . . . 10.0 109.746 -165.075 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 84' ' ' GLU . . . . . . . . . . . . . 5.0 mt-10 -23.0 -68.26 0.05 OUTLIER Pre-proline 0 CA--C 1.538 0.497 0 C-N-CA 126.923 2.089 . . . . 10.0 115.756 -175.937 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 85' ' ' PRO . . . . . . . . . . . . . 97.7 Cg_endo -73.39 -10.79 24.29 Favored 'Trans proline' 0 N--CA 1.456 -0.73 0 C-N-CA 121.731 1.621 . . . . 10.0 112.67 -169.325 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 86' ' ' HIS . . . . . . . . . . . . . 5.6 t-160 -83.54 67.83 9.54 Favored 'General case' 0 N--CA 1.45 -0.43 0 O-C-N 121.393 -0.817 . . . . 10.0 111.175 -166.722 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 87' ' ' ARG . . . . . . . . . . . . . 9.7 mtt180 41.07 67.7 0.5 Allowed 'General case' 0 CA--C 1.536 0.408 0 C-N-CA 126.129 1.772 . . . . 10.0 114.769 160.337 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . 78.67 -38.24 1.9 Allowed Glycine 0 CA--C 1.532 1.126 0 N-CA-C 116.923 1.529 . . . . 10.0 116.923 145.167 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 89' ' ' ALA . . . . . . . . . . . . . . . -59.92 -46.79 88.24 Favored 'General case' 0 CA--C 1.53 0.182 0 CA-C-N 118.873 1.336 . . . . 10.0 113.384 -158.35 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 90' ' ' GLY . . . . . . . . . . . . . . . 116.95 72.13 0.46 Allowed Glycine 0 CA--C 1.525 0.685 0 N-CA-C 109.619 -1.392 . . . . 10.0 109.619 -173.408 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 91' ' ' MET . . . . . . . . . . . . . 38.7 mtp -76.7 70.66 3.22 Favored 'General case' 0 CA--C 1.532 0.279 0 O-C-N 122.034 -0.686 . . . . 10.0 110.105 176.903 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 92' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -76.53 133.73 30.39 Favored 'Isoleucine or valine' 0 CA--C 1.533 0.299 0 C-N-CA 123.866 0.866 . . . . 10.0 111.186 176.837 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . -162.15 157.42 29.25 Favored Glycine 0 C--N 1.338 0.651 0 N-CA-C 109.551 -1.42 . . . . 10.0 109.551 158.208 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 94' ' ' LYS . . . . . . . . . . . . . 48.4 pttt -150.42 142.42 23.94 Favored 'General case' 0 N--CA 1.452 -0.344 0 CA-C-O 118.81 -0.614 . . . . 10.0 111.05 -179.674 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 95' ' ' VAL . . . . . . . . . . . . . 22.6 t -106.84 148.27 11.35 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.328 0 N-CA-C 107.419 -1.326 . . . . 10.0 107.419 -178.238 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 96' ' ' VAL . . . . . . . . . . . . . 92.6 t -124.5 117.93 51.98 Favored 'Isoleucine or valine' 0 CA--C 1.536 0.442 0 C-N-CA 126.132 1.773 . . . . 10.0 109.066 -173.302 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 97' ' ' VAL . . . . . . . . . . . . . 14.5 t -92.18 152.49 3.4 Favored 'Isoleucine or valine' 0 CA--C 1.541 0.597 0 CA-C-N 120.504 1.502 . . . . 10.0 111.41 -173.052 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 98' ' ' ASP . . . . . . . . . . . . . 25.4 t70 . . . . . 0 C--O 1.25 1.088 0 C-N-CA 127.862 2.465 . . . . 10.0 108.479 172.746 . . . . . . . . 0 0 . 1 . 001 nuclear orig full ' A' A ' 99' ' ' ' CU' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 001 nuclear build full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.468 0.435 0 N-CA-C 107.491 -1.3 . . . . 10.0 107.491 . . . . . . . . . 0 0 . 1 . 001 nuclear build full ' A' A ' 2' ' ' ASN . . . . . . . . . . . . . 10.1 p30 -73.74 162.71 28.86 Favored 'General case' 0 C--O 1.232 0.17 0 N-CA-C 108.266 -1.013 . . . . 10.0 108.266 173.994 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -107.57 167.12 10.17 Favored 'General case' 0 C--O 1.231 0.103 0 N-CA-C 109.157 -0.682 . . . . 10.0 109.157 169.152 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 4' ' ' THR . . . . . . . . . . . . . 15.1 t -148.74 153.76 38.65 Favored 'General case' 0 N--CA 1.444 -0.77 0 O-C-N 121.149 -0.969 . . . . 10.0 110.684 175.776 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 5' ' ' VAL . . . . . . . . . . . . . 90.5 t -136.44 151.86 28.85 Favored 'Isoleucine or valine' 0 C--O 1.235 0.316 0 N-CA-C 106.387 -1.708 . . . . 10.0 106.387 178.233 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 6' ' ' LYS . . . . . . . . . . . . . 55.6 pttt -110.55 131.91 54.65 Favored 'General case' 0 C--O 1.233 0.218 0 N-CA-C 109.376 -0.602 . . . . 10.0 109.376 177.095 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 7' ' ' MET . . . . . . . . . . . . . 19.4 mtt -73.07 84.77 1.3 Allowed 'General case' 0 N--CA 1.451 -0.389 0 N-CA-C 109.112 -0.699 . . . . 10.0 109.112 -173.864 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 101.81 148.67 21.54 Favored Glycine 0 CA--C 1.525 0.704 0 C-N-CA 124.675 1.131 . . . . 10.0 111.048 179.089 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 9' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -73.89 146.14 44.27 Favored 'General case' 0 CA--C 1.533 0.308 0 C-N-CA 123.977 0.911 . . . . 10.0 109.99 -173.947 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 10' ' ' ASP . . . . . . . . . . . . . 0.1 OUTLIER -39.18 -54.25 1.79 Allowed 'General case' 0 N--CA 1.467 0.424 0 C-N-CA 126.081 1.752 . . . . 10.0 112.41 -179.305 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 14.3 t -54.47 -26.65 32.48 Favored 'General case' 0 CA--C 1.537 0.47 0 C-N-CA 124.632 1.173 . . . . 10.0 112.467 -176.87 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 104.47 62.27 0.66 Allowed Glycine 0 C--N 1.336 0.535 0 N-CA-C 108.847 -1.701 . . . . 10.0 108.847 -175.774 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 13' ' ' ALA . . . . . . . . . . . . . . . -132.18 154.11 49.88 Favored 'General case' 0 N--CA 1.456 -0.128 0 N-CA-C 108.283 -1.006 . . . . 10.0 108.283 174.061 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 14' ' ' LEU . . . . . . . . . . . . . 8.3 mp -66.57 -49.86 65.0 Favored 'General case' 0 N--CA 1.453 -0.32 0 C-N-CA 122.303 0.241 . . . . 10.0 110.777 -172.109 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 34.3 m -46.01 130.72 2.69 Favored 'Isoleucine or valine' 0 CA--C 1.539 0.528 0 C-N-CA 122.889 0.476 . . . . 10.0 112.258 -168.433 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 16' ' ' PHE . . . . . . . . . . . . . 5.5 m-85 -71.39 145.9 49.08 Favored 'General case' 0 N--CA 1.453 -0.288 0 N-CA-C 107.844 -1.169 . . . . 10.0 107.844 178.685 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 24.4 mt-10 -134.85 138.06 28.76 Favored Pre-proline 0 C--O 1.235 0.326 0 O-C-N 123.5 0.5 . . . . 10.0 109.742 167.779 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 18' ' ' PRO . . . . . . . . . . . . . 22.6 Cg_exo -64.91 141.98 49.55 Favored 'Cis proline' 0 CA--C 1.539 0.74 0 N-CA-C 109.349 -1.058 . . . . 10.0 109.349 -15.842 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 19' ' ' SER . . . . . . . . . . . . . 5.5 p -69.94 -33.52 72.23 Favored 'General case' 0 CA--C 1.533 0.309 0 C-N-CA 123.578 0.751 . . . . 10.0 111.744 -174.259 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 2.1 m -125.59 145.17 50.25 Favored 'General case' 0 N--CA 1.451 -0.421 0 N-CA-C 107.86 -1.163 . . . . 10.0 107.86 166.771 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 30.2 m -137.3 160.76 35.38 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.46 0 N-CA-C 105.931 -1.877 . . . . 10.0 105.931 172.751 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 22' ' ' THR . . . . . . . . . . . . . 1.3 p -111.68 153.43 26.43 Favored 'General case' 0 CA--C 1.517 -0.294 0 N-CA-C 109.264 -0.643 . . . . 10.0 109.264 172.506 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 23' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -154.18 157.24 4.56 Favored 'Isoleucine or valine' 0 N--CA 1.446 -0.653 0 N-CA-C 105.913 -1.884 . . . . 10.0 105.913 -162.825 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 24' ' ' LYS . . . . . . . . . . . . . 14.0 mttt -97.08 159.77 14.72 Favored 'General case' 0 CA--C 1.535 0.403 0 CA-C-N 120.618 1.554 . . . . 10.0 113.45 177.864 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 25' ' ' ALA . . . . . . . . . . . . . . . -56.57 102.41 0.08 Allowed 'General case' 0 CA--C 1.542 0.673 0 C-N-CA 124.854 1.262 . . . . 10.0 110.563 172.19 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 98.22 -4.7 60.64 Favored Glycine 0 CA--C 1.525 0.714 0 C-N-CA 125.958 1.742 . . . . 10.0 112.772 -179.851 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 27' ' ' GLU . . . . . . . . . . . . . 3.9 mm-40 -73.61 172.06 12.08 Favored 'General case' 0 C--O 1.239 0.534 0 CA-C-N 117.992 0.896 . . . . 10.0 109.196 168.136 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 28' ' ' GLU . . . . . . . . . . . . . 52.6 mt-10 -101.77 161.66 13.49 Favored 'General case' 0 C--O 1.234 0.279 0 CA-C-N 115.215 -0.902 . . . . 10.0 113.178 177.923 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 93.4 t -117.44 142.9 29.48 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.392 0 N-CA-C 107.444 -1.317 . . . . 10.0 107.444 152.911 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 28.0 ttmt -111.26 134.51 52.8 Favored 'General case' 0 CA--C 1.534 0.36 0 CA-C-O 118.683 -0.675 . . . . 10.0 109.404 167.753 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 31' ' ' TRP . . . . . 0.544 ' HZ3' ' HG ' ' A' ' 71' ' ' SER . 29.4 m-90 -105.77 129.2 54.01 Favored 'General case' 0 CA--C 1.531 0.239 0 CA-C-N 119.585 1.084 . . . . 10.0 108.552 167.868 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 53.5 t -106.93 126.87 62.9 Favored 'Isoleucine or valine' 0 C--N 1.343 0.295 0 C-N-CA 124.526 1.13 . . . . 10.0 108.91 179.946 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 33' ' ' ASN . . . . . . . . . . . . . 34.7 t30 -73.94 102.51 4.14 Favored 'General case' 0 CA--C 1.532 0.258 0 CA-C-O 118.902 -0.571 . . . . 10.0 109.858 -178.443 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 34' ' ' ASN . . . . . . . . . . . . . 17.8 t30 -79.5 -74.16 0.31 Allowed 'General case' 0 CA--C 1.532 0.277 0 CA-C-N 118.683 0.674 . . . . 10.0 110.303 176.68 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 35' ' ' LYS . . . . . . . . . . . . . 3.7 mmtt -166.17 173.98 9.7 Favored 'General case' 0 C--O 1.226 -0.177 0 N-CA-C 108.261 -1.014 . . . . 10.0 108.261 -169.915 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 36' ' ' LEU . . . . . . . . . . . . . 1.7 mm? 68.37 57.63 0.45 Allowed 'General case' 0 N--CA 1.469 0.477 0 C-N-CA 125.331 1.452 . . . . 10.0 108.184 -168.563 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 37' ' ' SER . . . . . . . . . . . . . 1.7 p -77.06 158.01 80.55 Favored Pre-proline 0 N--CA 1.447 -0.577 0 C-N-CA 124.027 0.931 . . . . 10.0 109.744 173.531 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 38' ' ' PRO . . . . . . . . . . . . . 85.6 Cg_endo -76.39 146.28 84.24 Favored 'Cis proline' 0 N--CA 1.456 -0.677 0 N-CA-C 110.02 -0.8 . . . . 10.0 110.02 -8.944 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 39' ' ' HIS . . . . . . . . . . . . . 84.6 m-70 -109.69 146.42 34.9 Favored 'General case' 0 N--CA 1.457 -0.084 0 N-CA-C 109.447 -0.575 . . . . 10.0 109.447 166.03 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 40' ' ' ASN . . . . . . . . . . . . . 3.1 m-20 -116.63 171.47 7.85 Favored 'General case' 0 N--CA 1.452 -0.343 0 N-CA-C 104.343 -2.466 . . . . 10.0 104.343 156.66 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 41' ' ' ILE . . . . . 0.492 HG22 ' CE1' ' A' ' 43' ' ' PHE . 2.8 mt -139.95 88.12 0.51 Allowed 'Isoleucine or valine' 0 C--O 1.225 -0.191 0 N-CA-C 104.41 -2.441 . . . . 10.0 104.41 171.387 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 42' ' ' VAL . . . . . . . . . . . . . 29.3 t -95.36 132.02 40.56 Favored 'Isoleucine or valine' 0 CA--C 1.53 0.187 0 N-CA-C 108.384 -0.969 . . . . 10.0 108.384 -172.452 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 43' ' ' PHE . . . . . 0.492 ' CE1' HG22 ' A' ' 41' ' ' ILE . 4.5 m-85 -107.48 133.1 52.47 Favored 'General case' 0 C--N 1.343 0.284 0 C-N-CA 124.191 0.996 . . . . 10.0 108.932 -170.525 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 44' ' ' ALA . . . . . . . . . . . . . . . -88.68 133.13 34.3 Favored 'General case' 0 CA--C 1.537 0.446 0 CA-C-N 118.555 0.616 . . . . 10.0 109.853 -177.346 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 45' ' ' ALA . . . . . . . . . . . . . . . -76.93 61.63 1.98 Allowed 'General case' 0 C--N 1.341 0.234 0 C-N-CA 123.58 0.752 . . . . 10.0 109.286 174.672 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 46' ' ' ASP . . . . . . . . . . . . . 13.2 t70 -83.72 -57.97 3.0 Favored 'General case' 0 N--CA 1.458 -0.072 0 CA-C-O 120.966 0.412 . . . . 10.0 111.149 -158.876 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . -121.83 32.61 4.55 Favored Glycine 0 CA--C 1.523 0.557 0 N-CA-C 109.1 -1.6 . . . . 10.0 109.1 168.697 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 48' ' ' VAL . . . . . . . . . . . . . 1.7 t -145.94 153.02 13.62 Favored 'Isoleucine or valine' 0 CA--C 1.532 0.287 0 N-CA-C 108.754 -0.832 . . . . 10.0 108.754 -178.318 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 49' ' ' ASP . . . . . . . . . . . . . 0.9 OUTLIER -61.29 155.0 22.23 Favored 'General case' 0 C--O 1.234 0.247 0 C-N-CA 124.87 1.268 . . . . 10.0 112.893 -173.114 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -60.62 -57.77 11.29 Favored 'General case' 0 N--CA 1.451 -0.385 0 C-N-CA 123.873 0.869 . . . . 10.0 110.946 -177.969 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 51' ' ' ASP . . . . . . . . . . . . . 0.9 OUTLIER -52.21 -55.64 19.79 Favored 'General case' 0 CA--C 1.527 0.079 0 CA-C-N 118.9 0.773 . . . . 10.0 111.445 -178.374 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 52' ' ' THR . . . . . . . . . . . . . 0.3 OUTLIER -51.88 -57.25 9.92 Favored 'General case' 0 N--CA 1.465 0.32 0 N-CA-C 109.757 -0.46 . . . . 10.0 109.757 177.409 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 53' ' ' ALA . . . . . . . . . . . . . . . -57.56 -34.75 69.52 Favored 'General case' 0 N--CA 1.448 -0.574 0 N-CA-C 109.841 -0.429 . . . . 10.0 109.841 -178.271 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 54' ' ' ALA . . . . . . . . . . . . . . . -69.06 -46.97 66.5 Favored 'General case' 0 C--N 1.332 -0.171 0 N-CA-C 109.608 -0.516 . . . . 10.0 109.608 -177.443 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 55' ' ' LYS . . . . . . . . . . . . . 66.4 tttt -61.69 -41.92 98.23 Favored 'General case' 0 CA--C 1.536 0.436 0 C-N-CA 123.793 0.837 . . . . 10.0 109.924 178.847 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 56' ' ' LEU . . . . . 0.579 HD13 ' CE2' ' A' ' 79' ' ' TYR . 0.6 OUTLIER -71.14 -26.53 63.04 Favored 'General case' 0 CA--C 1.539 0.554 0 C-N-CA 124.473 1.109 . . . . 10.0 112.505 173.829 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 57' ' ' SER . . . . . . . . . . . . . 14.4 t -73.73 103.78 4.41 Favored 'General case' 0 C--O 1.233 0.201 0 CA-C-N 119.272 0.942 . . . . 10.0 110.666 -178.054 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 58' ' ' HIS . . . . . . . . . . . . . 81.9 m-70 -72.23 92.59 1.39 Allowed 'General case' 0 N--CA 1.45 -0.474 0 O-C-N 121.236 -0.915 . . . . 10.0 108.862 174.517 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 59' ' ' LYS . . . . . . . . . . . . . 82.3 mttt -68.24 -6.82 25.74 Favored 'General case' 0 CA--C 1.54 0.58 0 CA-C-N 115.184 -0.916 . . . . 10.0 111.206 157.175 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . -56.23 156.22 11.82 Favored Glycine 0 CA--C 1.533 1.166 0 N-CA-C 111.08 -0.808 . . . . 10.0 111.08 168.988 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 61' ' ' LEU . . . . . . . . . . . . . 0.3 OUTLIER -132.23 90.34 2.79 Favored 'General case' 0 CA--C 1.531 0.239 0 N-CA-C 107.394 -1.336 . . . . 10.0 107.394 -162.143 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 62' ' ' ALA . . . . . . . . . . . . . . . -90.55 112.59 24.33 Favored 'General case' 0 CA--C 1.531 0.239 0 C-N-CA 123.365 0.666 . . . . 10.0 110.06 -170.247 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 63' ' ' PHE . . . . . . . . . . . . . 0.1 OUTLIER -111.8 -47.88 3.11 Favored 'General case' 0 C--N 1.341 0.205 0 CA-C-N 118.611 0.642 . . . . 10.0 111.375 168.213 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . -71.43 126.82 30.66 Favored 'General case' 0 CA--C 1.539 0.546 0 CA-C-N 118.511 0.596 . . . . 10.0 110.48 -176.166 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 65' ' ' ALA . . . . . . . . . . . . . . . -70.82 91.01 0.82 Allowed 'General case' 0 CA--C 1.532 0.273 0 O-C-N 121.664 -0.648 . . . . 10.0 109.393 -178.766 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . 169.07 -50.8 0.22 Allowed Glycine 0 CA--C 1.523 0.537 0 N-CA-C 110.204 -1.158 . . . . 10.0 110.204 -172.135 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 67' ' ' GLU . . . . . . . . . . . . . 51.7 mt-10 -71.32 96.16 1.4 Allowed 'General case' 0 N--CA 1.449 -0.481 0 N-CA-C 108.047 -1.094 . . . . 10.0 108.047 -177.363 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -78.67 167.22 21.55 Favored 'General case' 0 N--CA 1.446 -0.655 0 N-CA-C 108.404 -0.962 . . . . 10.0 108.404 170.792 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 69' ' ' PHE . . . . . . . . . . . . . 17.8 m-85 -130.28 162.59 28.65 Favored 'General case' 0 C--O 1.231 0.124 0 N-CA-C 108.976 -0.75 . . . . 10.0 108.976 166.934 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 70' ' ' THR . . . . . . . . . . . . . 1.4 m -131.53 152.19 50.95 Favored 'General case' 0 N--CA 1.463 0.203 0 C-N-CA 125.756 1.622 . . . . 10.0 109.945 178.917 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 71' ' ' SER . . . . . 0.544 ' HG ' ' HZ3' ' A' ' 31' ' ' TRP . 14.5 p -145.53 144.99 30.86 Favored 'General case' 0 CA--C 1.543 0.674 0 C-N-CA 125.467 1.507 . . . . 10.0 107.032 176.378 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 72' ' ' THR . . . . . . . . . . . . . 4.3 m -103.05 134.23 46.83 Favored 'General case' 0 N--CA 1.467 0.413 0 C-N-CA 124.613 1.165 . . . . 10.0 108.481 175.48 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 73' ' ' PHE . . . . . 0.489 ' CE2' ' CD1' ' A' ' 79' ' ' TYR . 4.4 m-85 -102.07 91.93 4.55 Favored 'General case' 0 CA--C 1.519 -0.248 0 N-CA-C 107.455 -1.313 . . . . 10.0 107.455 175.17 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 74' ' ' THR . . . . . . . . . . . . . 3.1 m -68.17 -45.71 72.72 Favored 'General case' 0 CA--C 1.532 0.253 0 CA-C-N 118.537 0.608 . . . . 10.0 110.535 -178.149 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 75' ' ' GLU . . . . . . . . . . . . . 35.6 tt0 -90.47 135.07 29.87 Favored Pre-proline 0 CA--C 1.538 0.483 0 C-N-CA 123.355 0.662 . . . . 10.0 110.716 -171.679 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 76' ' ' PRO . . . . . . . . . . . . . 96.2 Cg_endo -75.49 84.86 1.66 Allowed 'Trans proline' 0 N--CA 1.453 -0.883 0 C-N-CA 122.93 2.42 . . . . 10.0 111.093 -178.652 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 77' ' ' GLY . . . . . . . . . . . . . . . -128.92 -159.61 10.0 Favored Glycine 0 CA--C 1.529 0.964 0 C-N-CA 123.75 0.69 . . . . 10.0 111.611 179.318 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 78' ' ' THR . . . . . . . . . . . . . 22.3 m -122.95 135.52 54.52 Favored 'General case' 0 N--CA 1.453 -0.29 0 N-CA-C 105.416 -2.068 . . . . 10.0 105.416 164.738 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 79' ' ' TYR . . . . . 0.579 ' CE2' HD13 ' A' ' 56' ' ' LEU . 44.4 m-85 -116.27 142.36 46.94 Favored 'General case' 0 CA--C 1.521 -0.153 0 N-CA-C 106.38 -1.711 . . . . 10.0 106.38 179.153 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 80' ' ' THR . . . . . . . . . . . . . 98.0 m -123.43 142.0 51.43 Favored 'General case' 0 C--O 1.237 0.408 0 N-CA-C 106.79 -1.559 . . . . 10.0 106.79 -178.735 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 81' ' ' TYR . . . . . . . . . . . . . 53.0 p90 -147.03 158.81 44.04 Favored 'General case' 0 N--CA 1.445 -0.692 0 O-C-N 123.776 0.672 . . . . 10.0 111.053 -173.344 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 82' ' ' TYR . . . . . . . . . . . . . 1.3 p90 -158.68 172.78 17.64 Favored 'General case' 0 N--CA 1.449 -0.482 0 C-N-CA 124.094 0.958 . . . . 10.0 109.391 -168.819 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 83' ' ' CYS . . . . . . . . . . . . . 10.4 t -132.09 63.81 1.61 Allowed 'General case' 0 CA--C 1.532 0.263 0 C-N-CA 123.81 0.844 . . . . 10.0 109.746 -165.075 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 84' ' ' GLU . . . . . . . . . . . . . 5.0 mt-10 -23.0 -68.26 0.05 OUTLIER Pre-proline 0 CA--C 1.538 0.497 0 C-N-CA 126.923 2.089 . . . . 10.0 115.756 -175.937 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 85' ' ' PRO . . . . . . . . . . . . . 97.7 Cg_endo -73.39 -10.79 24.29 Favored 'Trans proline' 0 N--CA 1.456 -0.73 0 C-N-CA 121.731 1.621 . . . . 10.0 112.67 -169.325 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 86' ' ' HIS . . . . . . . . . . . . . 5.6 t-160 -83.54 67.83 9.54 Favored 'General case' 0 N--CA 1.45 -0.43 0 O-C-N 121.393 -0.817 . . . . 10.0 111.175 -166.722 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 87' ' ' ARG . . . . . . . . . . . . . 9.7 mtt180 41.07 67.7 0.5 Allowed 'General case' 0 CA--C 1.536 0.408 0 C-N-CA 126.129 1.772 . . . . 10.0 114.769 160.337 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . 78.67 -38.24 1.9 Allowed Glycine 0 CA--C 1.532 1.126 0 N-CA-C 116.923 1.529 . . . . 10.0 116.923 145.167 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 89' ' ' ALA . . . . . . . . . . . . . . . -59.92 -46.79 88.24 Favored 'General case' 0 CA--C 1.53 0.182 0 CA-C-N 118.873 1.336 . . . . 10.0 113.384 -158.35 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 90' ' ' GLY . . . . . . . . . . . . . . . 116.95 72.13 0.46 Allowed Glycine 0 CA--C 1.525 0.685 0 N-CA-C 109.619 -1.392 . . . . 10.0 109.619 -173.408 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 91' ' ' MET . . . . . . . . . . . . . 38.7 mtp -76.7 70.66 3.22 Favored 'General case' 0 CA--C 1.532 0.279 0 O-C-N 122.034 -0.686 . . . . 10.0 110.105 176.903 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 92' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -76.53 133.73 30.39 Favored 'Isoleucine or valine' 0 CA--C 1.533 0.299 0 C-N-CA 123.866 0.866 . . . . 10.0 111.186 176.837 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . -162.15 157.42 29.25 Favored Glycine 0 C--N 1.338 0.651 0 N-CA-C 109.551 -1.42 . . . . 10.0 109.551 158.208 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 94' ' ' LYS . . . . . . . . . . . . . 48.4 pttt -150.42 142.42 23.94 Favored 'General case' 0 N--CA 1.452 -0.344 0 CA-C-O 118.81 -0.614 . . . . 10.0 111.05 -179.674 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 95' ' ' VAL . . . . . . . . . . . . . 22.6 t -106.84 148.27 11.35 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.328 0 N-CA-C 107.419 -1.326 . . . . 10.0 107.419 -178.238 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 96' ' ' VAL . . . . . . . . . . . . . 92.6 t -124.5 117.93 51.98 Favored 'Isoleucine or valine' 0 CA--C 1.536 0.442 0 C-N-CA 126.132 1.773 . . . . 10.0 109.066 -173.302 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 97' ' ' VAL . . . . . 0.4 ' CG2' ' HD2' ' A' ' 73' ' ' PHE . 14.5 t -92.18 152.49 3.4 Favored 'Isoleucine or valine' 0 CA--C 1.541 0.597 0 CA-C-N 120.504 1.502 . . . . 10.0 111.41 -173.052 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 98' ' ' ASP . . . . . . . . . . . . . 25.4 t70 . . . . . 0 C--O 1.25 1.088 0 C-N-CA 127.862 2.465 . . . . 10.0 108.479 172.746 . . . . . . . . 0 0 . 1 . 001 nuclear build full ' A' A ' 99' ' ' ' CU' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 001 nuclear nobuild full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.468 0.435 0 N-CA-C 107.491 -1.3 . . . . 10.0 107.491 . . . . . . . . . 0 0 . 1 . 001 nuclear nobuild full ' A' A ' 2' ' ' ASN . . . . . . . . . . . . . 10.1 p30 -73.74 162.71 28.86 Favored 'General case' 0 C--O 1.232 0.17 0 N-CA-C 108.266 -1.013 . . . . 10.0 108.266 173.994 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -107.57 167.12 10.17 Favored 'General case' 0 C--O 1.231 0.103 0 N-CA-C 109.157 -0.682 . . . . 10.0 109.157 169.152 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 4' ' ' THR . . . . . . . . . . . . . 15.1 t -148.74 153.76 38.65 Favored 'General case' 0 N--CA 1.444 -0.77 0 O-C-N 121.149 -0.969 . . . . 10.0 110.684 175.776 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 5' ' ' VAL . . . . . . . . . . . . . 90.5 t -136.44 151.86 28.85 Favored 'Isoleucine or valine' 0 C--O 1.235 0.316 0 N-CA-C 106.387 -1.708 . . . . 10.0 106.387 178.233 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 6' ' ' LYS . . . . . . . . . . . . . 55.6 pttt -110.55 131.91 54.65 Favored 'General case' 0 C--O 1.233 0.218 0 N-CA-C 109.376 -0.602 . . . . 10.0 109.376 177.095 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 7' ' ' MET . . . . . . . . . . . . . 19.4 mtt -73.07 84.77 1.3 Allowed 'General case' 0 N--CA 1.451 -0.389 0 N-CA-C 109.112 -0.699 . . . . 10.0 109.112 -173.864 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 101.81 148.67 21.54 Favored Glycine 0 CA--C 1.525 0.704 0 C-N-CA 124.675 1.131 . . . . 10.0 111.048 179.089 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 9' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -73.89 146.14 44.27 Favored 'General case' 0 CA--C 1.533 0.308 0 C-N-CA 123.977 0.911 . . . . 10.0 109.99 -173.947 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 10' ' ' ASP . . . . . . . . . . . . . 0.1 OUTLIER -39.18 -54.25 1.79 Allowed 'General case' 0 N--CA 1.467 0.424 0 C-N-CA 126.081 1.752 . . . . 10.0 112.41 -179.305 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 14.3 t -54.47 -26.65 32.48 Favored 'General case' 0 CA--C 1.537 0.47 0 C-N-CA 124.632 1.173 . . . . 10.0 112.467 -176.87 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 104.47 62.27 0.66 Allowed Glycine 0 C--N 1.336 0.535 0 N-CA-C 108.847 -1.701 . . . . 10.0 108.847 -175.774 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 13' ' ' ALA . . . . . . . . . . . . . . . -132.18 154.11 49.88 Favored 'General case' 0 N--CA 1.456 -0.128 0 N-CA-C 108.283 -1.006 . . . . 10.0 108.283 174.061 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 14' ' ' LEU . . . . . . . . . . . . . 8.3 mp -66.57 -49.86 65.0 Favored 'General case' 0 N--CA 1.453 -0.32 0 C-N-CA 122.303 0.241 . . . . 10.0 110.777 -172.109 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 34.3 m -46.01 130.72 2.69 Favored 'Isoleucine or valine' 0 CA--C 1.539 0.528 0 C-N-CA 122.889 0.476 . . . . 10.0 112.258 -168.433 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 16' ' ' PHE . . . . . . . . . . . . . 5.5 m-85 -71.39 145.9 49.08 Favored 'General case' 0 N--CA 1.453 -0.288 0 N-CA-C 107.844 -1.169 . . . . 10.0 107.844 178.685 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 24.4 mt-10 -134.85 138.06 28.76 Favored Pre-proline 0 C--O 1.235 0.326 0 O-C-N 123.5 0.5 . . . . 10.0 109.742 167.779 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 18' ' ' PRO . . . . . . . . . . . . . 22.6 Cg_exo -64.91 141.98 49.55 Favored 'Cis proline' 0 CA--C 1.539 0.74 0 N-CA-C 109.349 -1.058 . . . . 10.0 109.349 -15.842 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 19' ' ' SER . . . . . . . . . . . . . 5.5 p -69.94 -33.52 72.23 Favored 'General case' 0 CA--C 1.533 0.309 0 C-N-CA 123.578 0.751 . . . . 10.0 111.744 -174.259 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 2.1 m -125.59 145.17 50.25 Favored 'General case' 0 N--CA 1.451 -0.421 0 N-CA-C 107.86 -1.163 . . . . 10.0 107.86 166.771 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 30.2 m -137.3 160.76 35.38 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.46 0 N-CA-C 105.931 -1.877 . . . . 10.0 105.931 172.751 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 22' ' ' THR . . . . . . . . . . . . . 1.3 p -111.68 153.43 26.43 Favored 'General case' 0 CA--C 1.517 -0.294 0 N-CA-C 109.264 -0.643 . . . . 10.0 109.264 172.506 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 23' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -154.18 157.24 4.56 Favored 'Isoleucine or valine' 0 N--CA 1.446 -0.653 0 N-CA-C 105.913 -1.884 . . . . 10.0 105.913 -162.825 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 24' ' ' LYS . . . . . . . . . . . . . 14.0 mttt -97.08 159.77 14.72 Favored 'General case' 0 CA--C 1.535 0.403 0 CA-C-N 120.618 1.554 . . . . 10.0 113.45 177.864 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 25' ' ' ALA . . . . . . . . . . . . . . . -56.57 102.41 0.08 Allowed 'General case' 0 CA--C 1.542 0.673 0 C-N-CA 124.854 1.262 . . . . 10.0 110.563 172.19 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 98.22 -4.7 60.64 Favored Glycine 0 CA--C 1.525 0.714 0 C-N-CA 125.958 1.742 . . . . 10.0 112.772 -179.851 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 27' ' ' GLU . . . . . . . . . . . . . 3.9 mm-40 -73.61 172.06 12.08 Favored 'General case' 0 C--O 1.239 0.534 0 CA-C-N 117.992 0.896 . . . . 10.0 109.196 168.136 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 28' ' ' GLU . . . . . . . . . . . . . 52.6 mt-10 -101.77 161.66 13.49 Favored 'General case' 0 C--O 1.234 0.279 0 CA-C-N 115.215 -0.902 . . . . 10.0 113.178 177.923 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 93.4 t -117.44 142.9 29.48 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.392 0 N-CA-C 107.444 -1.317 . . . . 10.0 107.444 152.911 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 28.0 ttmt -111.26 134.51 52.8 Favored 'General case' 0 CA--C 1.534 0.36 0 CA-C-O 118.683 -0.675 . . . . 10.0 109.404 167.753 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 31' ' ' TRP . . . . . 0.544 ' HZ3' ' HG ' ' A' ' 71' ' ' SER . 29.4 m-90 -105.77 129.2 54.01 Favored 'General case' 0 CA--C 1.531 0.239 0 CA-C-N 119.585 1.084 . . . . 10.0 108.552 167.868 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 53.5 t -106.93 126.87 62.9 Favored 'Isoleucine or valine' 0 C--N 1.343 0.295 0 C-N-CA 124.526 1.13 . . . . 10.0 108.91 179.946 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 33' ' ' ASN . . . . . . . . . . . . . 34.7 t30 -73.94 102.51 4.14 Favored 'General case' 0 CA--C 1.532 0.258 0 CA-C-O 118.902 -0.571 . . . . 10.0 109.858 -178.443 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 34' ' ' ASN . . . . . . . . . . . . . 17.8 t30 -79.5 -74.16 0.31 Allowed 'General case' 0 CA--C 1.532 0.277 0 CA-C-N 118.683 0.674 . . . . 10.0 110.303 176.68 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 35' ' ' LYS . . . . . . . . . . . . . 3.7 mmtt -166.17 173.98 9.7 Favored 'General case' 0 C--O 1.226 -0.177 0 N-CA-C 108.261 -1.014 . . . . 10.0 108.261 -169.915 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 36' ' ' LEU . . . . . . . . . . . . . 1.7 mm? 68.37 57.63 0.45 Allowed 'General case' 0 N--CA 1.469 0.477 0 C-N-CA 125.331 1.452 . . . . 10.0 108.184 -168.563 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 37' ' ' SER . . . . . . . . . . . . . 1.7 p -77.06 158.01 80.55 Favored Pre-proline 0 N--CA 1.447 -0.577 0 C-N-CA 124.027 0.931 . . . . 10.0 109.744 173.531 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 38' ' ' PRO . . . . . . . . . . . . . 85.6 Cg_endo -76.39 146.28 84.24 Favored 'Cis proline' 0 N--CA 1.456 -0.677 0 N-CA-C 110.02 -0.8 . . . . 10.0 110.02 -8.944 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 39' ' ' HIS . . . . . . . . . . . . . 84.6 m-70 -109.69 146.42 34.9 Favored 'General case' 0 N--CA 1.457 -0.084 0 N-CA-C 109.447 -0.575 . . . . 10.0 109.447 166.03 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 40' ' ' ASN . . . . . . . . . . . . . 3.1 m-20 -116.63 171.47 7.85 Favored 'General case' 0 N--CA 1.452 -0.343 0 N-CA-C 104.343 -2.466 . . . . 10.0 104.343 156.66 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 41' ' ' ILE . . . . . 0.492 HG22 ' CE1' ' A' ' 43' ' ' PHE . 2.8 mt -139.95 88.12 0.51 Allowed 'Isoleucine or valine' 0 C--O 1.225 -0.191 0 N-CA-C 104.41 -2.441 . . . . 10.0 104.41 171.387 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 42' ' ' VAL . . . . . . . . . . . . . 29.3 t -95.36 132.02 40.56 Favored 'Isoleucine or valine' 0 CA--C 1.53 0.187 0 N-CA-C 108.384 -0.969 . . . . 10.0 108.384 -172.452 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 43' ' ' PHE . . . . . 0.492 ' CE1' HG22 ' A' ' 41' ' ' ILE . 4.5 m-85 -107.48 133.1 52.47 Favored 'General case' 0 C--N 1.343 0.284 0 C-N-CA 124.191 0.996 . . . . 10.0 108.932 -170.525 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 44' ' ' ALA . . . . . . . . . . . . . . . -88.68 133.13 34.3 Favored 'General case' 0 CA--C 1.537 0.446 0 CA-C-N 118.555 0.616 . . . . 10.0 109.853 -177.346 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 45' ' ' ALA . . . . . . . . . . . . . . . -76.93 61.63 1.98 Allowed 'General case' 0 C--N 1.341 0.234 0 C-N-CA 123.58 0.752 . . . . 10.0 109.286 174.672 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 46' ' ' ASP . . . . . . . . . . . . . 13.2 t70 -83.72 -57.97 3.0 Favored 'General case' 0 N--CA 1.458 -0.072 0 CA-C-O 120.966 0.412 . . . . 10.0 111.149 -158.876 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . -121.83 32.61 4.55 Favored Glycine 0 CA--C 1.523 0.557 0 N-CA-C 109.1 -1.6 . . . . 10.0 109.1 168.697 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 48' ' ' VAL . . . . . . . . . . . . . 1.7 t -145.94 153.02 13.62 Favored 'Isoleucine or valine' 0 CA--C 1.532 0.287 0 N-CA-C 108.754 -0.832 . . . . 10.0 108.754 -178.318 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 49' ' ' ASP . . . . . . . . . . . . . 0.9 OUTLIER -61.29 155.0 22.23 Favored 'General case' 0 C--O 1.234 0.247 0 C-N-CA 124.87 1.268 . . . . 10.0 112.893 -173.114 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -60.62 -57.77 11.29 Favored 'General case' 0 N--CA 1.451 -0.385 0 C-N-CA 123.873 0.869 . . . . 10.0 110.946 -177.969 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 51' ' ' ASP . . . . . . . . . . . . . 0.9 OUTLIER -52.21 -55.64 19.79 Favored 'General case' 0 CA--C 1.527 0.079 0 CA-C-N 118.9 0.773 . . . . 10.0 111.445 -178.374 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 52' ' ' THR . . . . . . . . . . . . . 0.3 OUTLIER -51.88 -57.25 9.92 Favored 'General case' 0 N--CA 1.465 0.32 0 N-CA-C 109.757 -0.46 . . . . 10.0 109.757 177.409 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 53' ' ' ALA . . . . . . . . . . . . . . . -57.56 -34.75 69.52 Favored 'General case' 0 N--CA 1.448 -0.574 0 N-CA-C 109.841 -0.429 . . . . 10.0 109.841 -178.271 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 54' ' ' ALA . . . . . . . . . . . . . . . -69.06 -46.97 66.5 Favored 'General case' 0 C--N 1.332 -0.171 0 N-CA-C 109.608 -0.516 . . . . 10.0 109.608 -177.443 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 55' ' ' LYS . . . . . . . . . . . . . 66.4 tttt -61.69 -41.92 98.23 Favored 'General case' 0 CA--C 1.536 0.436 0 C-N-CA 123.793 0.837 . . . . 10.0 109.924 178.847 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 56' ' ' LEU . . . . . 0.579 HD13 ' CE2' ' A' ' 79' ' ' TYR . 0.6 OUTLIER -71.14 -26.53 63.04 Favored 'General case' 0 CA--C 1.539 0.554 0 C-N-CA 124.473 1.109 . . . . 10.0 112.505 173.829 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 57' ' ' SER . . . . . . . . . . . . . 14.4 t -73.73 103.78 4.41 Favored 'General case' 0 C--O 1.233 0.201 0 CA-C-N 119.272 0.942 . . . . 10.0 110.666 -178.054 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 58' ' ' HIS . . . . . . . . . . . . . 81.9 m-70 -72.23 92.59 1.39 Allowed 'General case' 0 N--CA 1.45 -0.474 0 O-C-N 121.236 -0.915 . . . . 10.0 108.862 174.517 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 59' ' ' LYS . . . . . . . . . . . . . 82.3 mttt -68.24 -6.82 25.74 Favored 'General case' 0 CA--C 1.54 0.58 0 CA-C-N 115.184 -0.916 . . . . 10.0 111.206 157.175 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . -56.23 156.22 11.82 Favored Glycine 0 CA--C 1.533 1.166 0 N-CA-C 111.08 -0.808 . . . . 10.0 111.08 168.988 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 61' ' ' LEU . . . . . . . . . . . . . 0.3 OUTLIER -132.23 90.34 2.79 Favored 'General case' 0 CA--C 1.531 0.239 0 N-CA-C 107.394 -1.336 . . . . 10.0 107.394 -162.143 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 62' ' ' ALA . . . . . . . . . . . . . . . -90.55 112.59 24.33 Favored 'General case' 0 CA--C 1.531 0.239 0 C-N-CA 123.365 0.666 . . . . 10.0 110.06 -170.247 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 63' ' ' PHE . . . . . . . . . . . . . 0.1 OUTLIER -111.8 -47.88 3.11 Favored 'General case' 0 C--N 1.341 0.205 0 CA-C-N 118.611 0.642 . . . . 10.0 111.375 168.213 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . -71.43 126.82 30.66 Favored 'General case' 0 CA--C 1.539 0.546 0 CA-C-N 118.511 0.596 . . . . 10.0 110.48 -176.166 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 65' ' ' ALA . . . . . . . . . . . . . . . -70.82 91.01 0.82 Allowed 'General case' 0 CA--C 1.532 0.273 0 O-C-N 121.664 -0.648 . . . . 10.0 109.393 -178.766 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . 169.07 -50.8 0.22 Allowed Glycine 0 CA--C 1.523 0.537 0 N-CA-C 110.204 -1.158 . . . . 10.0 110.204 -172.135 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 67' ' ' GLU . . . . . . . . . . . . . 51.7 mt-10 -71.32 96.16 1.4 Allowed 'General case' 0 N--CA 1.449 -0.481 0 N-CA-C 108.047 -1.094 . . . . 10.0 108.047 -177.363 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -78.67 167.22 21.55 Favored 'General case' 0 N--CA 1.446 -0.655 0 N-CA-C 108.404 -0.962 . . . . 10.0 108.404 170.792 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 69' ' ' PHE . . . . . . . . . . . . . 17.8 m-85 -130.28 162.59 28.65 Favored 'General case' 0 C--O 1.231 0.124 0 N-CA-C 108.976 -0.75 . . . . 10.0 108.976 166.934 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 70' ' ' THR . . . . . . . . . . . . . 1.4 m -131.53 152.19 50.95 Favored 'General case' 0 N--CA 1.463 0.203 0 C-N-CA 125.756 1.622 . . . . 10.0 109.945 178.917 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 71' ' ' SER . . . . . 0.544 ' HG ' ' HZ3' ' A' ' 31' ' ' TRP . 14.5 p -145.53 144.99 30.86 Favored 'General case' 0 CA--C 1.543 0.674 0 C-N-CA 125.467 1.507 . . . . 10.0 107.032 176.378 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 72' ' ' THR . . . . . . . . . . . . . 4.3 m -103.05 134.23 46.83 Favored 'General case' 0 N--CA 1.467 0.413 0 C-N-CA 124.613 1.165 . . . . 10.0 108.481 175.48 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 73' ' ' PHE . . . . . 0.489 ' CE2' ' CD1' ' A' ' 79' ' ' TYR . 4.4 m-85 -102.07 91.93 4.55 Favored 'General case' 0 CA--C 1.519 -0.248 0 N-CA-C 107.455 -1.313 . . . . 10.0 107.455 175.17 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 74' ' ' THR . . . . . . . . . . . . . 3.1 m -68.17 -45.71 72.72 Favored 'General case' 0 CA--C 1.532 0.253 0 CA-C-N 118.537 0.608 . . . . 10.0 110.535 -178.149 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 75' ' ' GLU . . . . . . . . . . . . . 35.6 tt0 -90.47 135.07 29.87 Favored Pre-proline 0 CA--C 1.538 0.483 0 C-N-CA 123.355 0.662 . . . . 10.0 110.716 -171.679 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 76' ' ' PRO . . . . . . . . . . . . . 96.2 Cg_endo -75.49 84.86 1.66 Allowed 'Trans proline' 0 N--CA 1.453 -0.883 0 C-N-CA 122.93 2.42 . . . . 10.0 111.093 -178.652 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 77' ' ' GLY . . . . . . . . . . . . . . . -128.92 -159.61 10.0 Favored Glycine 0 CA--C 1.529 0.964 0 C-N-CA 123.75 0.69 . . . . 10.0 111.611 179.318 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 78' ' ' THR . . . . . . . . . . . . . 22.3 m -122.95 135.52 54.52 Favored 'General case' 0 N--CA 1.453 -0.29 0 N-CA-C 105.416 -2.068 . . . . 10.0 105.416 164.738 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 79' ' ' TYR . . . . . 0.579 ' CE2' HD13 ' A' ' 56' ' ' LEU . 44.4 m-85 -116.27 142.36 46.94 Favored 'General case' 0 CA--C 1.521 -0.153 0 N-CA-C 106.38 -1.711 . . . . 10.0 106.38 179.153 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 80' ' ' THR . . . . . . . . . . . . . 98.0 m -123.43 142.0 51.43 Favored 'General case' 0 C--O 1.237 0.408 0 N-CA-C 106.79 -1.559 . . . . 10.0 106.79 -178.735 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 81' ' ' TYR . . . . . . . . . . . . . 53.0 p90 -147.03 158.81 44.04 Favored 'General case' 0 N--CA 1.445 -0.692 0 O-C-N 123.776 0.672 . . . . 10.0 111.053 -173.344 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 82' ' ' TYR . . . . . . . . . . . . . 1.3 p90 -158.68 172.78 17.64 Favored 'General case' 0 N--CA 1.449 -0.482 0 C-N-CA 124.094 0.958 . . . . 10.0 109.391 -168.819 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 83' ' ' CYS . . . . . . . . . . . . . 10.4 t -132.09 63.81 1.61 Allowed 'General case' 0 CA--C 1.532 0.263 0 C-N-CA 123.81 0.844 . . . . 10.0 109.746 -165.075 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 84' ' ' GLU . . . . . . . . . . . . . 5.0 mt-10 -23.0 -68.26 0.05 OUTLIER Pre-proline 0 CA--C 1.538 0.497 0 C-N-CA 126.923 2.089 . . . . 10.0 115.756 -175.937 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 85' ' ' PRO . . . . . . . . . . . . . 97.7 Cg_endo -73.39 -10.79 24.29 Favored 'Trans proline' 0 N--CA 1.456 -0.73 0 C-N-CA 121.731 1.621 . . . . 10.0 112.67 -169.325 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 86' ' ' HIS . . . . . . . . . . . . . 5.6 t-160 -83.54 67.83 9.54 Favored 'General case' 0 N--CA 1.45 -0.43 0 O-C-N 121.393 -0.817 . . . . 10.0 111.175 -166.722 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 87' ' ' ARG . . . . . . . . . . . . . 9.7 mtt180 41.07 67.7 0.5 Allowed 'General case' 0 CA--C 1.536 0.408 0 C-N-CA 126.129 1.772 . . . . 10.0 114.769 160.337 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . 78.67 -38.24 1.9 Allowed Glycine 0 CA--C 1.532 1.126 0 N-CA-C 116.923 1.529 . . . . 10.0 116.923 145.167 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 89' ' ' ALA . . . . . . . . . . . . . . . -59.92 -46.79 88.24 Favored 'General case' 0 CA--C 1.53 0.182 0 CA-C-N 118.873 1.336 . . . . 10.0 113.384 -158.35 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 90' ' ' GLY . . . . . . . . . . . . . . . 116.95 72.13 0.46 Allowed Glycine 0 CA--C 1.525 0.685 0 N-CA-C 109.619 -1.392 . . . . 10.0 109.619 -173.408 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 91' ' ' MET . . . . . . . . . . . . . 38.7 mtp -76.7 70.66 3.22 Favored 'General case' 0 CA--C 1.532 0.279 0 O-C-N 122.034 -0.686 . . . . 10.0 110.105 176.903 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 92' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -76.53 133.73 30.39 Favored 'Isoleucine or valine' 0 CA--C 1.533 0.299 0 C-N-CA 123.866 0.866 . . . . 10.0 111.186 176.837 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . -162.15 157.42 29.25 Favored Glycine 0 C--N 1.338 0.651 0 N-CA-C 109.551 -1.42 . . . . 10.0 109.551 158.208 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 94' ' ' LYS . . . . . . . . . . . . . 48.4 pttt -150.42 142.42 23.94 Favored 'General case' 0 N--CA 1.452 -0.344 0 CA-C-O 118.81 -0.614 . . . . 10.0 111.05 -179.674 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 95' ' ' VAL . . . . . . . . . . . . . 22.6 t -106.84 148.27 11.35 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.328 0 N-CA-C 107.419 -1.326 . . . . 10.0 107.419 -178.238 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 96' ' ' VAL . . . . . . . . . . . . . 92.6 t -124.5 117.93 51.98 Favored 'Isoleucine or valine' 0 CA--C 1.536 0.442 0 C-N-CA 126.132 1.773 . . . . 10.0 109.066 -173.302 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 97' ' ' VAL . . . . . 0.4 ' CG2' ' HD2' ' A' ' 73' ' ' PHE . 14.5 t -92.18 152.49 3.4 Favored 'Isoleucine or valine' 0 CA--C 1.541 0.597 0 CA-C-N 120.504 1.502 . . . . 10.0 111.41 -173.052 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 98' ' ' ASP . . . . . . . . . . . . . 25.4 t70 . . . . . 0 C--O 1.25 1.088 0 C-N-CA 127.862 2.465 . . . . 10.0 108.479 172.746 . . . . . . . . 0 0 . 1 . 001 nuclear nobuild full ' A' A ' 99' ' ' ' CU' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 stop_ save_